11/21
10:21 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
11/20
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/12
11:33 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
11/9
10:30 am
rare
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Low
Report
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
11/6
01:10 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
11/6
12:23 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
11/6
11:24 am
rare
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
11/6
09:30 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
11/6
08:07 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at HC Wainwright from $82.00 to $95.00. They now have a "buy" rating on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at HC Wainwright from $82.00 to $95.00. They now have a "buy" rating on the stock.
11/6
02:46 am
rare
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... [Yahoo! Finance]
11/5
08:14 pm
rare
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Low
Report
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
11/5
07:12 pm
rare
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/5
04:01 pm
rare
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Medium
Report
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
11/1
09:29 am
rare
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? [Yahoo! Finance]
Low
Report
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? [Yahoo! Finance]
10/29
04:05 pm
rare
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
Low
Report
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
10/23
11:56 am
rare
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year [Yahoo! Finance]
Low
Report
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year [Yahoo! Finance]
10/22
11:39 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
10/21
02:22 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $61.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $61.00 to $73.00. They now have a "buy" rating on the stock.
10/18
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/7
02:29 pm
rare
Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]
Low
Report
Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]
10/7
08:00 am
rare
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Low
Report
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
10/3
04:30 pm
rare
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Low
Report
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
10/1
09:12 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
9/26
10:15 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
9/26
08:00 am
rare
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Low
Report
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting